Cite
HARVARD Citation
Sonpavde, G. et al. (2022). Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma. European journal of cancer. pp. 55-65. [Online].